Teva Absorbs Ivax In $7.4-Billion Bid - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Teva Absorbs Ivax In $7.4-Billion Bid

ePT--the Electronic Newsletter of Pharmaceutical Technology

Teva Absorbs Ivax In $7.4-Billion Bid

TEVA Pharmaceutical Industries (Netanya, Israel) has signed an agreement to acquire IVAX Corporation (Miami, FL) for approximately $7.4 billion, further cementing Teva’s control of the generics industry.

In a prepared statement, TEVA’s President and CEO Israel Makov said, “The combination of our two complementary businesses will allow TEVA to expand and strengthen our global generic and branded businesses with additional products, a deeper pipeline, and a wider presence in new therapeutic areas and growth markets.”

With the IVAX purchase Teva, gains a strong presence in Latin America and in Central and Eastern Europe, and further expands its operations in North America and Europe. IVAX also brings complementary product lines in generics, a significant respiratory business, and a pipeline of generic and proprietary products in the areas of respiratory, CNS, and oncology. TEVA expects to generate sales of over $7 billion, and will operate in over 50 countries with an employee base of approximately 25,000 people.

–George Koroneos

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here